UNSPSC 51161568: Eprozinol hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H30N2O2.2CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X9AMI360PI. European Medicines Agency schedules eprozinol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01921MIG. The term eprozinol hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule eprozinol hydrochloride under HS 29335995 and SITC 51576.

As of Q4 2014, EPROZINOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC(CN1CCN(CC1)CCC(C2CCCCC2)O)C3CCCCC3.CL.CL.

UNSPSC 51161568 Eprozinol hydrochloride is a Commodity code representing a single pharmaceutical active ingredient, but the recent state and local procurement activity under this code shows minimal direct market demand for this specific drug product. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. This cooperative vehicle aggregates demand across multiple jurisdictions — state departments, local government facilities, and other public entities — to negotiate volume-based pricing with manufacturers who can supply identified pharmaceutical products meeting specified National Drug Codes (NDC), packaging configurations, and manufacturing requirements. Vendors must comply with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), and carry comprehensive insurance including $5,000,000 commercial general liability coverage. The RFP does not identify set-aside designations limiting responses to particular business classifications.

The MMCAP RFP, posted January 20, 2026 with proposals due March 26, 2026, represents the primary recent opportunity signaling demand for generic pharmaceuticals under this code tier. Evaluation weighs price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing compliance, administrative fee data format adherence, EDI capability, and 3 percent administrative fee acceptance. Awarded vendors will supply products through authorized wholesalers effective July 1, 2026, under a two-year contract term with optional extensions; incumbent vendors' amendments extend through June 30, 2028. The solicitation reflects cooperative purchasing consolidation across multiple state and local jurisdictions rather than individual agency procurement, and the specific eprozinol hydrochloride product may be represented as one line item within the broader generic pharmaceuticals catalog being negotiated rather than as a standalone procurement driver.